Professor Adrian Paul Banning

Professor Adrian Paul Banning

John Radcliffe Hospital, Oxford (United Kingdom of Great Britain & Northern Ireland)

Member of:

Professor Banning was appointed Consultant Cardiologist in 1999. He then became the Clinical Lead for cardiac medicine and in 2010 was appointed Divisional Director at Oxford University Hospital NHS Trust. He is the first Professor of Interventional Cardiology at Oxford University Professor Banning’s practice, cover a wide range of coronary conditions and procedures. He has championed the use of coronary stents as an alternative to coronary bypass and has been a leading investigator in most of the practice changing trials- Syntax, Excel, Syntax 2 , Noble. He is an expert in left main coronary stenting, bifurcation procedures and optimizing revascularisation in STEMI and multivessel disease.

Presentations Events Articles Podcasts

SYNTAX II trial: five year follow-up

Event: ESC Congress 2021 - The Digital Experience

Topic: Percutaneous Coronary Intervention (PCI)

Session: Trial Updates in ACS & PCI

Access

Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions.

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session: Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions

Access

PCI for left main revascularisation: pro.

Event: ESC Congress 2021 - The Digital Experience

Topic: Interventional Cardiology

Session: Great Debate: controversies in left main revascularisation – to stent or to operate?

Access

Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions.

Event: ESC Congress 2021 - The Digital Experience

Topic: Valvular Heart Disease

Session: Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions

Access

Complex coronary disease: CABG or PCI?

Event: ESC Congress 2020

Topic: Percutaneous Coronary Intervention (PCI)

Session: Revascularization Strategies in Acute and Chronic Coronary Syndromes: the Latest Update

Access

Left main is no longer a surgical domain - Rebuttal PRO.

Event: ESC Congress 2017

Topic: Coronary artery bypass surgery

Session: Left main is now a domain of interventional cardiology

Access

Left main is no longer a surgical domain - PRO

Event: ESC Congress 2017

Topic: Coronary artery bypass surgery

Session: Left main is now a domain of interventional cardiology

Access

Professor Adrian Paul Banning

Biography

Contributor content

SYNTAX II trial: five year follow-up

Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions.

PCI for left main revascularisation: pro.

Optimising patient outcomes in non-valvular atrial fibrillation (NVAF): Peri-procedural use of non-vitamin K antagonist oral anticoagulants (NOACs) in cardiac interventions.

Complex coronary disease: CABG or PCI?

Left main is no longer a surgical domain - Rebuttal PRO.

Left main is no longer a surgical domain - PRO

ESC 365 is supported by